Back to search results

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Abroad (travel likely)RecruitingPHASE1

Conditions

Acute Myeloid Leukemia · Myelodysplastic Syndrome · Blastic Plasmacytoid Dendritic Cell Neoplasm

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • City of Hope, Duarte, California, United States

    Contact: Study coordinator (Anthony Stein, MD) · AStein@coh.org · 626-359-8111
    Contact: Principal Investigator (Anthony Stein, MD)

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Andrew Lane, MD, PhD) · andrew_lane@dfci.harvard.edu
    Contact: Study coordinator (Veronica Zehnder) · veronica_zehnder@dfci.harvard.edu
    Contact: Principal Investigator (Andrew Lane, MD, PhD)

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Naveen Pemmaraju, MD) · npemmaraju@mdanderson.org · 713-792-4956
    Contact: Principal Investigator (Naveen Pemmaraju, MD)
Study leads

  • Andrew Lane, MD, PhD

    Principal Investigator

    Dana-Farber Cancer Institute

View source on ClinicalTrials.gov(opens in a new tab)